Matthew Plavan
2012 - Cesca Therapeutics
In 2012, Matthew Plavan earned a total compensation of $464K as Chief Executive Officer thru at Cesca Therapeutics, a 16% decrease compared to previous year.
Compensation breakdown
| Salary | $315,000 |
|---|---|
| Stock Awards | $149,000 |
| Total | $464,000 |
Plavan received $315K in salary, accounting for 68% of the total pay in 2012.
Plavan also received $149K in stock awards.
Rankings
In 2012, Matthew Plavan's compensation ranked 8,986th out of 11,487 executives tracked by ExecPay. In other words, Plavan earned more than 21.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,986 out of 11,487 | 22nd |
Division Manufacturing | 3,287 out of 4,253 | 23rd |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 473 out of 619 | 24th |
Industry group Laboratory Apparatus And Analytical, Optical, Measuring, and Controlling Instruments | 142 out of 189 | 25th |
Industry Laboratory Apparatus and Furniture | 4 out of 12 | 67th |
Source: SEC filing on May 11, 2015.
Plavan's colleagues
We found four more compensation records of executives who worked with Matthew Plavan at Cesca Therapeutics in 2012.
News
Arcadia Biosciences CEO Matthew Plavan's 2021 pay jumps 102% to $1.6M
April 19, 2022
Arcadia Biosciences CEO Matthew Plavan's 2020 pay jumps 37% to $794K
April 20, 2021
Arcadia Biosciences CEO Matthew Plavan's 2019 pay stays at $581K
April 17, 2020
Arcadia Biosciences CEO Rajendra Ketkar's 2018 pay jumps 40% to $904K
April 18, 2019